Dulaglutide (Trulicity)

Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist primarily approved for type 2 diabetes management, where it has established a strong evidence base through the AWARD trial series. Its weight loss benefit — approximately 3 to 4.7 kg in clinical trials — is modest compared to the newer obesity-approved agents, but its exceptional tolerability profile sets it apart in a meaningful way for a specific patient population. Among all GLP-1 agents, dulaglutide has the lowest reported nausea rate at approximately 10 percent — a full 10 percentage points below semaglutide and 15 points below tirzepatide. For patients who are GLP-1 naive and anxious about the GI side effects that drive early discontinuation, starting with dulaglutide offers the best chance of establishing tolerance before potentially transitioning to a higher-efficacy agent. The AWARD trials demonstrated consistent glycemic control with reductions in HbA1c of 1.4 to 1.5 percentage points, and the REWIND cardiovascular outcomes trial showed significant reduction in MACE (HR 0.88) for patients with established CV disease or multiple risk factors — providing a meaningful cardiovascular evidence base. Dulaglutide is administered via an innovative single-use, fully automated prefilled auto-injector pen that conceals the needle completely, which reduces injection anxiety substantially for new GLP-1 users. Dosing is once weekly at 0.75mg or 1.5mg, with a 3mg and 4.5mg high-dose option approved for additional glycemic and weight benefit. While not FDA approved for obesity as a primary indication, its off-label use for weight management in patients with type 2 diabetes who are GLP-1 intolerant of other agents reflects its clinical niche. Insurance coverage is broad for diabetes indications.